Nothing Special   »   [go: up one dir, main page]

DOP2016000237A - Terapia genica para la retinitis pigmentaria - Google Patents

Terapia genica para la retinitis pigmentaria

Info

Publication number
DOP2016000237A
DOP2016000237A DO2016000237A DO2016000237A DOP2016000237A DO P2016000237 A DOP2016000237 A DO P2016000237A DO 2016000237 A DO2016000237 A DO 2016000237A DO 2016000237 A DO2016000237 A DO 2016000237A DO P2016000237 A DOP2016000237 A DO P2016000237A
Authority
DO
Dominican Republic
Prior art keywords
gene therapy
pigmentary retinitis
retinitis
viral particles
pigmentary
Prior art date
Application number
DO2016000237A
Other languages
English (en)
Inventor
Catherine O'riordan
Matthew Adamowicz
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000237(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of DOP2016000237A publication Critical patent/DOP2016000237A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan en la presente memoria métodos para tratar la retinitis pigmentaria usando partículas de AAV que codifican miR-708. En un aspecto, las partículas víricas se administran en el ojo de un sujeto humano; por ejemplo, mediante inyección subretiniana. Están contempladas las partículas víricas que comprenden cápsides de AAV5 o mutantes de las mismas.
DO2016000237A 2014-03-21 2016-09-09 Terapia genica para la retinitis pigmentaria DOP2016000237A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
DOP2016000237A true DOP2016000237A (es) 2016-10-16

Family

ID=52829343

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000237A DOP2016000237A (es) 2014-03-21 2016-09-09 Terapia genica para la retinitis pigmentaria

Country Status (36)

Country Link
US (3) US10383953B2 (es)
EP (3) EP3628334B1 (es)
JP (3) JP6669664B2 (es)
KR (2) KR20160127832A (es)
CN (2) CN115252823A (es)
AR (1) AR099837A1 (es)
AU (2) AU2015230942B2 (es)
CA (1) CA2943185A1 (es)
CL (1) CL2016002333A1 (es)
CR (1) CR20160480A (es)
DK (2) DK3628334T5 (es)
DO (1) DOP2016000237A (es)
EA (1) EA201691891A1 (es)
EC (1) ECSP16083000A (es)
ES (2) ES2957840T3 (es)
FI (1) FI3628334T3 (es)
HR (2) HRP20231077T1 (es)
HU (2) HUE046454T2 (es)
IL (3) IL247543B (es)
LT (2) LT3119437T (es)
MA (1) MA39390B2 (es)
MX (2) MX2016012201A (es)
MY (1) MY190726A (es)
NZ (1) NZ724622A (es)
PE (1) PE20161252A1 (es)
PH (1) PH12016501684A1 (es)
PL (2) PL3119437T3 (es)
PT (2) PT3119437T (es)
RS (2) RS59634B1 (es)
SG (3) SG10201808218YA (es)
SI (2) SI3628334T1 (es)
TW (2) TWI780401B (es)
UA (1) UA120050C2 (es)
UY (1) UY36044A (es)
WO (1) WO2015143418A2 (es)
ZA (1) ZA201605924B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10383953B2 (en) * 2014-03-21 2019-08-20 Genzyme Corporation Gene therapy for retinitis pigmentosa
JP2018506304A (ja) 2015-02-10 2018-03-08 ジェンザイム・コーポレーション バリアントＲＮＡｉ
JP7075341B2 (ja) 2015-12-03 2022-05-25 フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ ＳｙｎＰ１６２、桿体光受容器における遺伝子の特異的発現のためのプロモーター
ES2900486T3 (es) * 2015-12-03 2022-03-17 Friedrich Miescher Institute For Biomedical Res SynP160, un promotor para la expresión específica de genes en los fotorreceptores de los bastones
KR102312253B1 (ko) * 2015-12-04 2021-10-15 쏘흐본느 유니베흐시테 프로모터 및 이의 용도
JP7272795B2 (ja) 2016-03-01 2023-05-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 優性網膜色素変性の治療のためのａａｖベクター
AU2017293773A1 (en) * 2016-07-05 2019-02-21 The Johns Hopkins University CRISPR/Cas9-based compositions and methods for treating retinal degenerations
CN111050805A (zh) * 2017-03-21 2020-04-21 斯蒂利亚诺斯·米夏拉克基斯 用于治疗cngb1相关视网膜色素变性的基因疗法
CN111356763B (zh) * 2017-09-22 2024-03-12 建新公司 变体RNAi
US20200263196A1 (en) * 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
EP3768327A4 (en) * 2018-03-23 2022-04-13 The Trustees of Columbia University in the City of New York GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES
EP3802836A4 (en) * 2018-06-01 2022-10-19 University of Florida Research Foundation, Incorporated COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT RETINITIS PIGMENTOSA
GB201817469D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
EP3934699A4 (en) * 2019-03-04 2022-12-21 The Trustees of The University of Pennsylvania NEUROPROTECTIVE GENE THERAPY TARGETING THE AKT PATHWAY
JP2022525564A (ja) * 2019-03-21 2022-05-17 ピーティーシー セラピューティクス， インコーポレイテッド アンジェルマン症候群を治療するためのベクターおよび方法
CN114521214A (zh) * 2020-07-24 2022-05-20 尔知渃米斯股份有限公司 视紫红质转录体特异性反式剪接核酶及其用途
TWI832531B (zh) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
JP4860886B2 (ja) 2000-06-01 2012-01-25 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二本鎖パルボウイルスベクター
CA2864537C (en) 2001-11-13 2016-11-29 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
CN1934260B (zh) * 2004-01-22 2013-03-13 株式会社载体研究所 利用含有巨细胞病毒增强子和鸡β-肌动蛋白启动子的杂合启动子制造负链RNA病毒载体的方法
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
US8257969B2 (en) * 2007-04-12 2012-09-04 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US9078914B2 (en) * 2009-09-10 2015-07-14 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
CN102947453A (zh) 2010-01-28 2013-02-27 费城儿童医院 用于病毒载体纯化的可扩缩生产平台和用于基因治疗中的如此纯化的病毒载体
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012057363A1 (ja) * 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2012112832A1 (en) 2011-02-17 2012-08-23 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
WO2013123503A1 (en) * 2012-02-17 2013-08-22 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
EP2834358A4 (en) * 2012-04-02 2016-03-09 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
MA37663B1 (fr) 2012-05-25 2019-12-31 Univ California Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn
US9770491B2 (en) * 2012-07-11 2017-09-26 The Trustees Of The University Of Pennsylvania AAV-mediated gene therapy for RPGR X-linked retinal degeneration
CA2889020A1 (en) * 2012-10-23 2014-05-01 Cornell University Treatment of metastatic breast cancer
CA2924743A1 (en) 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US10383953B2 (en) 2014-03-21 2019-08-20 Genzyme Corporation Gene therapy for retinitis pigmentosa

Also Published As

Publication number Publication date
EP3628334A1 (en) 2020-04-01
AU2021200988B2 (en) 2024-08-01
IL275918A (en) 2020-08-31
MX2016012201A (es) 2017-01-19
SI3628334T1 (sl) 2023-11-30
SG10201808218YA (en) 2018-10-30
TW202021627A (zh) 2020-06-16
JP6669664B2 (ja) 2020-03-18
IL247543A0 (en) 2016-11-30
ECSP16083000A (es) 2017-02-24
US20170173183A1 (en) 2017-06-22
UA120050C2 (uk) 2019-09-25
AU2021200988A1 (en) 2021-03-11
ES2957840T3 (es) 2024-01-26
PL3628334T3 (pl) 2023-12-18
PT3119437T (pt) 2019-12-12
HRP20192141T1 (hr) 2020-02-21
ZA201605924B (en) 2017-09-27
TWI780401B (zh) 2022-10-11
JP2020059737A (ja) 2020-04-16
US20220054657A1 (en) 2022-02-24
SI3119437T1 (sl) 2020-01-31
SG11201607005UA (en) 2016-09-29
CL2016002333A1 (es) 2017-05-26
NZ724622A (en) 2022-05-27
PT3628334T (pt) 2023-09-26
CA2943185A1 (en) 2015-09-24
CN106456660B (zh) 2022-05-31
AR099837A1 (es) 2016-08-24
JP7048563B2 (ja) 2022-04-05
EA201691891A1 (ru) 2017-01-30
IL284741B2 (en) 2023-02-01
MX2020010694A (es) 2020-11-06
EP3119437A2 (en) 2017-01-25
US11103598B2 (en) 2021-08-31
UY36044A (es) 2015-10-30
EP3119437B1 (en) 2019-09-04
ES2760263T3 (es) 2020-05-13
US20200046851A1 (en) 2020-02-13
DK3119437T3 (da) 2019-12-09
MA39390B2 (fr) 2022-04-29
FI3628334T3 (fi) 2023-09-15
WO2015143418A2 (en) 2015-09-24
IL284741B (en) 2022-10-01
US10383953B2 (en) 2019-08-20
RS59634B1 (sr) 2020-01-31
AU2015230942B2 (en) 2020-11-19
HRP20231077T1 (hr) 2023-12-22
CN106456660A (zh) 2017-02-22
EP4345165A3 (en) 2024-09-25
PE20161252A1 (es) 2016-11-30
PL3119437T3 (pl) 2020-04-30
HUE063460T2 (hu) 2024-01-28
IL284741A (en) 2021-08-31
MA39390A1 (fr) 2017-12-29
WO2015143418A3 (en) 2015-11-19
PH12016501684A1 (en) 2016-10-03
EP3628334B1 (en) 2023-06-28
NZ762841A (en) 2023-11-24
LT3628334T (lt) 2023-09-25
JP2022084810A (ja) 2022-06-07
JP7534348B2 (ja) 2024-08-14
CN115252823A (zh) 2022-11-01
AU2015230942A1 (en) 2016-10-13
LT3119437T (lt) 2019-12-27
HUE046454T2 (hu) 2020-03-30
DK3628334T3 (da) 2023-10-02
DK3628334T5 (da) 2024-09-02
KR20230006039A (ko) 2023-01-10
KR20160127832A (ko) 2016-11-04
IL275918B (en) 2021-07-29
RS64611B1 (sr) 2023-10-31
EP4345165A2 (en) 2024-04-03
IL247543B (en) 2020-07-30
SG10201912968WA (en) 2020-02-27
TW201622752A (zh) 2016-07-01
MY190726A (en) 2022-05-12
TWI706789B (zh) 2020-10-11
JP2017509632A (ja) 2017-04-06
BR112016021017A2 (pt) 2017-10-03
CR20160480A (es) 2016-12-14

Similar Documents

Publication Publication Date Title
DOP2016000237A (es) Terapia genica para la retinitis pigmentaria
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
DOP2016000280A (es) Vectores de aav para la terapia génica de la retina y el snc
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
EP3562514A4 (en) GENE THERAPY TO TREAT WILSON'S DISEASE
BR112018008731A2 (pt) terapia gênica
MX2018005286A (es) Constructo genetico.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
DK3419672T5 (da) Genterapi til behandling af retinal degenerationssygdom
MX2019006886A (es) Métodos para tratar enfermedades asociadas con células linfoides innatas del grupo 2 (ilc2).
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2018013885A (es) Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis